Origins and prevalence of the American Founder Mutation of MSH2

Mark Clendenning, Mark E. Baze, Shuying Sun, Kyle Walsh, Sandya Liyanarachchi, Dan Fix, Victoria Schunemann, Ilene Comeras, Molly Deacon, Jane F. Lynch, Gordon Gong, Brittany C. Thomas, Stephen N Thibodeau, Henry T. Lynch, Heather Hampel, Albert De La Chapelle

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Large germline deletions within the mismatch repair gene MSH2 account for a significant proportion (up to 20%) of all deleterious mutations of this gene which are associated with Lynch syndrome. An exons 1 to 6 deletion of MSH2, originally reported in nine families, has been associated with a founding event within the United States, which genealogic studies had previously dated to 1727, and the number of present day carriers was estimated to be 18,981. Here, we report the development of a robust multiplex PCR which has assisted in the detection of 32 new families who carry the MSH2 American Founder Mutation (AFM). By offering testing to family members, 126 carriers of the AFM have been identified. Extensive genealogic studies have connected 27 of the 41 AFM families into seven extended pedigrees. These extended families have been traced back to around the 18th century without any evidence of further convergence between them. Characterization of the genomic sequence flanking the deletion and the identification of a common disease haplotype of between 0.6 and 2.3 Mb in all probands provides evidence for a common ancestor between these extended families. The DMLE+2.2 software predicts an age of ∼500 years (95% confidence interval, 425-625) for this mutation. Taken together, these data are suggestive of an earlier founding event than was first thought, which likely occurred in a European or a Native American population. The consequences of this finding would be that the AFM is significantly more frequent in the United States than was previously predicted.

Original languageEnglish (US)
Pages (from-to)2145-2153
Number of pages9
JournalCancer Research
Volume68
Issue number7
DOIs
StatePublished - Apr 1 2008

Fingerprint

Mutation
Hereditary Nonpolyposis Colorectal Neoplasms
DNA Mismatch Repair
North American Indians
Sequence Deletion
Multiplex Polymerase Chain Reaction
Pedigree
Haplotypes
Genes
Exons
Software
Confidence Intervals
Population

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Clendenning, M., Baze, M. E., Sun, S., Walsh, K., Liyanarachchi, S., Fix, D., ... De La Chapelle, A. (2008). Origins and prevalence of the American Founder Mutation of MSH2. Cancer Research, 68(7), 2145-2153. https://doi.org/10.1158/0008-5472.CAN-07-6599

Origins and prevalence of the American Founder Mutation of MSH2. / Clendenning, Mark; Baze, Mark E.; Sun, Shuying; Walsh, Kyle; Liyanarachchi, Sandya; Fix, Dan; Schunemann, Victoria; Comeras, Ilene; Deacon, Molly; Lynch, Jane F.; Gong, Gordon; Thomas, Brittany C.; Thibodeau, Stephen N; Lynch, Henry T.; Hampel, Heather; De La Chapelle, Albert.

In: Cancer Research, Vol. 68, No. 7, 01.04.2008, p. 2145-2153.

Research output: Contribution to journalArticle

Clendenning, M, Baze, ME, Sun, S, Walsh, K, Liyanarachchi, S, Fix, D, Schunemann, V, Comeras, I, Deacon, M, Lynch, JF, Gong, G, Thomas, BC, Thibodeau, SN, Lynch, HT, Hampel, H & De La Chapelle, A 2008, 'Origins and prevalence of the American Founder Mutation of MSH2', Cancer Research, vol. 68, no. 7, pp. 2145-2153. https://doi.org/10.1158/0008-5472.CAN-07-6599
Clendenning M, Baze ME, Sun S, Walsh K, Liyanarachchi S, Fix D et al. Origins and prevalence of the American Founder Mutation of MSH2. Cancer Research. 2008 Apr 1;68(7):2145-2153. https://doi.org/10.1158/0008-5472.CAN-07-6599
Clendenning, Mark ; Baze, Mark E. ; Sun, Shuying ; Walsh, Kyle ; Liyanarachchi, Sandya ; Fix, Dan ; Schunemann, Victoria ; Comeras, Ilene ; Deacon, Molly ; Lynch, Jane F. ; Gong, Gordon ; Thomas, Brittany C. ; Thibodeau, Stephen N ; Lynch, Henry T. ; Hampel, Heather ; De La Chapelle, Albert. / Origins and prevalence of the American Founder Mutation of MSH2. In: Cancer Research. 2008 ; Vol. 68, No. 7. pp. 2145-2153.
@article{f4b8e1ef869941ed8de4f744439ef031,
title = "Origins and prevalence of the American Founder Mutation of MSH2",
abstract = "Large germline deletions within the mismatch repair gene MSH2 account for a significant proportion (up to 20{\%}) of all deleterious mutations of this gene which are associated with Lynch syndrome. An exons 1 to 6 deletion of MSH2, originally reported in nine families, has been associated with a founding event within the United States, which genealogic studies had previously dated to 1727, and the number of present day carriers was estimated to be 18,981. Here, we report the development of a robust multiplex PCR which has assisted in the detection of 32 new families who carry the MSH2 American Founder Mutation (AFM). By offering testing to family members, 126 carriers of the AFM have been identified. Extensive genealogic studies have connected 27 of the 41 AFM families into seven extended pedigrees. These extended families have been traced back to around the 18th century without any evidence of further convergence between them. Characterization of the genomic sequence flanking the deletion and the identification of a common disease haplotype of between 0.6 and 2.3 Mb in all probands provides evidence for a common ancestor between these extended families. The DMLE+2.2 software predicts an age of ∼500 years (95{\%} confidence interval, 425-625) for this mutation. Taken together, these data are suggestive of an earlier founding event than was first thought, which likely occurred in a European or a Native American population. The consequences of this finding would be that the AFM is significantly more frequent in the United States than was previously predicted.",
author = "Mark Clendenning and Baze, {Mark E.} and Shuying Sun and Kyle Walsh and Sandya Liyanarachchi and Dan Fix and Victoria Schunemann and Ilene Comeras and Molly Deacon and Lynch, {Jane F.} and Gordon Gong and Thomas, {Brittany C.} and Thibodeau, {Stephen N} and Lynch, {Henry T.} and Heather Hampel and {De La Chapelle}, Albert",
year = "2008",
month = "4",
day = "1",
doi = "10.1158/0008-5472.CAN-07-6599",
language = "English (US)",
volume = "68",
pages = "2145--2153",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Origins and prevalence of the American Founder Mutation of MSH2

AU - Clendenning, Mark

AU - Baze, Mark E.

AU - Sun, Shuying

AU - Walsh, Kyle

AU - Liyanarachchi, Sandya

AU - Fix, Dan

AU - Schunemann, Victoria

AU - Comeras, Ilene

AU - Deacon, Molly

AU - Lynch, Jane F.

AU - Gong, Gordon

AU - Thomas, Brittany C.

AU - Thibodeau, Stephen N

AU - Lynch, Henry T.

AU - Hampel, Heather

AU - De La Chapelle, Albert

PY - 2008/4/1

Y1 - 2008/4/1

N2 - Large germline deletions within the mismatch repair gene MSH2 account for a significant proportion (up to 20%) of all deleterious mutations of this gene which are associated with Lynch syndrome. An exons 1 to 6 deletion of MSH2, originally reported in nine families, has been associated with a founding event within the United States, which genealogic studies had previously dated to 1727, and the number of present day carriers was estimated to be 18,981. Here, we report the development of a robust multiplex PCR which has assisted in the detection of 32 new families who carry the MSH2 American Founder Mutation (AFM). By offering testing to family members, 126 carriers of the AFM have been identified. Extensive genealogic studies have connected 27 of the 41 AFM families into seven extended pedigrees. These extended families have been traced back to around the 18th century without any evidence of further convergence between them. Characterization of the genomic sequence flanking the deletion and the identification of a common disease haplotype of between 0.6 and 2.3 Mb in all probands provides evidence for a common ancestor between these extended families. The DMLE+2.2 software predicts an age of ∼500 years (95% confidence interval, 425-625) for this mutation. Taken together, these data are suggestive of an earlier founding event than was first thought, which likely occurred in a European or a Native American population. The consequences of this finding would be that the AFM is significantly more frequent in the United States than was previously predicted.

AB - Large germline deletions within the mismatch repair gene MSH2 account for a significant proportion (up to 20%) of all deleterious mutations of this gene which are associated with Lynch syndrome. An exons 1 to 6 deletion of MSH2, originally reported in nine families, has been associated with a founding event within the United States, which genealogic studies had previously dated to 1727, and the number of present day carriers was estimated to be 18,981. Here, we report the development of a robust multiplex PCR which has assisted in the detection of 32 new families who carry the MSH2 American Founder Mutation (AFM). By offering testing to family members, 126 carriers of the AFM have been identified. Extensive genealogic studies have connected 27 of the 41 AFM families into seven extended pedigrees. These extended families have been traced back to around the 18th century without any evidence of further convergence between them. Characterization of the genomic sequence flanking the deletion and the identification of a common disease haplotype of between 0.6 and 2.3 Mb in all probands provides evidence for a common ancestor between these extended families. The DMLE+2.2 software predicts an age of ∼500 years (95% confidence interval, 425-625) for this mutation. Taken together, these data are suggestive of an earlier founding event than was first thought, which likely occurred in a European or a Native American population. The consequences of this finding would be that the AFM is significantly more frequent in the United States than was previously predicted.

UR - http://www.scopus.com/inward/record.url?scp=42049093195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42049093195&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-07-6599

DO - 10.1158/0008-5472.CAN-07-6599

M3 - Article

C2 - 18381419

AN - SCOPUS:42049093195

VL - 68

SP - 2145

EP - 2153

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 7

ER -